e-Drug3D

914

FOSAMPRENAVIR

INN
FOSAMPRENAVIR

(has an active metabolite)

cas 226700-79-4

CLASS

ANTIINFECTIVES
ENZYME INHIBITOR (HIV PROTEASE)
ANTIVIRAL
RAPIDLY AND ALMOST COMPLETELY HYDROLYSED TO AMPRENAVIR

ROUTE (list)

ORAL

ATC code

J05AE07

PK parameters

Solubility

0.31 MILLIGRAM / MILLILITER

Target

TARGET HIV-1 PROTEASE

DrugCentral

Pol polyprotein UNIPROT Q72874 pol

Download SDF file

[(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-1-phenyl-3-phosphonooxybutan-2-yl]carbamate

Formula:
C25H36N3O9PS

Calculated chemical properties:

MW 583.59
NB_atoms 39
XLogP 1.26
PSA 161.655
NB_HD 3
NB_HA 12
fsp3 0.48
Lipinski(0=no;1=yes) 0

FDA
NDA 021548 (label) INN (FOSAMPRENAVIR CALCIUM) LEXIVA (VIIV HLTHCARE) APPROVAL= AP YEAR= 2003 DISCONTINUED
NDA 022116 (label) INN (FOSAMPRENAVIR CALCIUM) LEXIVA (VIIV HLTHCARE) APPROVAL= AP YEAR= 2007 DISCONTINUED
NDA 204060 (label) INN (FOSAMPRENAVIR CALCIUM) FOSAMPRENAVIR CALCIUM (MYLAN) APPROVAL= AP YEAR= 2016
NDA 204130 (pdf not found) INN (FOSAMPRENAVIR CALCIUM) FOSAMPRENAVIR CALCIUM (LUPIN LTD) APPROVAL= TA YEAR= 2016
NDA 204024 (pdf not found) INN (FOSAMPRENAVIR CALCIUM) FOSAMPRENAVIR CALCIUM (SUN PHARM) APPROVAL= AP YEAR= 2019